AdvanSix Inc. (NYSE:ASIX – Get Free Report) SVP Achilles B. Kintiroglou sold 363 shares of AdvanSix stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $31.00, for a total value of $11,253.00. Following the transaction, the senior vice president now directly owns 33,238 shares in the company, valued at $1,030,378. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
AdvanSix Stock Up 2.9 %
Shares of NYSE:ASIX opened at $29.79 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.74 and a current ratio of 1.39. AdvanSix Inc. has a 52-week low of $20.86 and a 52-week high of $32.04. The business’s 50 day simple moving average is $29.29 and its two-hundred day simple moving average is $26.57. The firm has a market cap of $795.69 million, a P/E ratio of 99.30 and a beta of 1.69.
AdvanSix (NYSE:ASIX – Get Free Report) last announced its quarterly earnings results on Friday, August 2nd. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.35. AdvanSix had a net margin of 0.57% and a return on equity of 1.03%. The business had revenue of $453.48 million during the quarter, compared to analyst estimates of $426.80 million. During the same quarter in the previous year, the business posted $1.18 EPS. As a group, research analysts forecast that AdvanSix Inc. will post 1.67 EPS for the current fiscal year.
AdvanSix Dividend Announcement
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of AdvanSix from a “hold” rating to a “buy” rating in a research report on Monday, August 5th.
Get Our Latest Report on AdvanSix
Hedge Funds Weigh In On AdvanSix
A number of hedge funds have recently added to or reduced their stakes in ASIX. Meritage Portfolio Management raised its position in AdvanSix by 9.1% in the 3rd quarter. Meritage Portfolio Management now owns 10,429 shares of the company’s stock valued at $317,000 after buying an additional 871 shares during the last quarter. Sigma Planning Corp raised its stake in shares of AdvanSix by 117.4% during the 3rd quarter. Sigma Planning Corp now owns 8,730 shares of the company’s stock worth $265,000 after purchasing an additional 58,870 shares during the period. Summit Global Investments purchased a new position in AdvanSix in the third quarter valued at about $233,000. EMC Capital Management lifted its stake in AdvanSix by 194.6% in the third quarter. EMC Capital Management now owns 27,869 shares of the company’s stock valued at $847,000 after purchasing an additional 18,409 shares during the last quarter. Finally, Donald Smith & CO. Inc. lifted its position in shares of AdvanSix by 5.0% during the 3rd quarter. Donald Smith & CO. Inc. now owns 176,996 shares of the company’s stock valued at $5,377,000 after buying an additional 8,396 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.
About AdvanSix
AdvanSix Inc engages in the manufacture and sale of polymer resins in the United States and internationally. It offers Nylon 6, a polymer resin, which is a synthetic material used to produce fibers, filaments, engineered plastics, and films. The company also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone that are used in the production of adhesives, paints, coatings, solvents, herbicides, and engineered plastic resins, as well as other intermediate chemicals, including phenol, monoisopropylamine, dipropylamine, monoallylamine, alpha-methylstyrene, cyclohexanone, methyl ethyl ketoxime, acetaldehyde oxime, 2-pentanone oxime, cyclohexanol, sulfuric acid, ammonia, and carbon dioxide.
Recommended Stories
- Five stocks we like better than AdvanSix
- How to Use Stock Screeners to Find Stocks
- Intel: Is Now the Time to Be Brave?Â
- What to Know About Investing in Penny Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for AdvanSix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdvanSix and related companies with MarketBeat.com's FREE daily email newsletter.